Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Histone Modification02:32

Histone Modification

13.1K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Blood advances·2026
Same author

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same author

Different <i>SF3B1</i> Mutation Hotspots Show Hematopoietic Lineage-Specific VAF Patterns and Correlate with Distinct Genetic and Prognostic Profiles in Patients with Myeloid Neoplasms.

Cancers·2026
Same author

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Leukemia·2026
Same author

Corrigendum to 'Volatile pyrethroid spatial repellents for preventing mosquito bites: a systematic review and meta-analysis' EBioMedicine Volatile pyrethroid spatial repellents for preventing mosquito bites: a systematic review and meta-analysis 119 (2025) 105891/10.1016/j.ebiom.2025.105891 Sep: 119: 105891.

EBioMedicine·2025
Same author

PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma.

Nature communications·2025

Related Experiment Video

Updated: Jun 9, 2025

Expression Analysis of Mammalian Linker-histone Subtypes
14:40

Expression Analysis of Mammalian Linker-histone Subtypes

Published on: March 19, 2012

13.8K

Quantification of Histone H1 Subtypes Using Targeted Proteomics.

Jordi López-Gómez1, Laura Villarreal2,3, Marta Andrés1

  • 1Biochemistry and Molecular Biology Department, Biosciences Faculty, Autonomous University of Barcelona, 08193 Bellaterra, Spain.

Biomolecules
|October 26, 2024
PubMed
Summary
This summary is machine-generated.

Histone H1 subtypes regulate chromatin. A new mass spectrometry assay quantifies H1 levels, revealing potential biomarkers for chronic myeloid leukemia (CML) treatment response.

Keywords:
cancer biomarkerchronic myeloid leukemiafunctional differentiationhistone H1imatinib resistanceparallel reaction monitoring

More Related Videos

Author Spotlight: Enhanced Histone PTM Isomer Identification Through LC-TIMS-ToF MS/MS and PASEF
05:52

Author Spotlight: Enhanced Histone PTM Isomer Identification Through LC-TIMS-ToF MS/MS and PASEF

Published on: January 12, 2024

1.0K
Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue
08:12

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Published on: May 5, 2022

3.9K

Related Experiment Videos

Last Updated: Jun 9, 2025

Expression Analysis of Mammalian Linker-histone Subtypes
14:40

Expression Analysis of Mammalian Linker-histone Subtypes

Published on: March 19, 2012

13.8K
Author Spotlight: Enhanced Histone PTM Isomer Identification Through LC-TIMS-ToF MS/MS and PASEF
05:52

Author Spotlight: Enhanced Histone PTM Isomer Identification Through LC-TIMS-ToF MS/MS and PASEF

Published on: January 12, 2024

1.0K
Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue
08:12

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Published on: May 5, 2022

3.9K

Area of Science:

  • Molecular Biology
  • Proteomics
  • Cancer Research

Background:

  • Histone H1 subtypes regulate chromatin structure, and their altered levels in cancer suggest potential as biomarkers.
  • Variations in the H1 complement (proportions of somatic H1s) hint at functional specificity.

Purpose of the Study:

  • To develop and validate a mass spectrometry-based parallel reaction monitoring (PRM) assay for quantifying human Histone H1 subtypes.
  • To investigate the potential of H1 complement alterations as biomarkers in chronic myeloid leukemia (CML).

Main Methods:

  • Development of a highly specific mass spectrometry-based parallel reaction monitoring (MS-PRM) assay using unique peptides for each H1 subtype.
  • Validation of the MS-PRM assay on human cell lines (HeLa, K562, T47D) for reproducibility, sensitivity, and accuracy against electrophoretic and Western blot data.
  • Application of the validated MS-PRM assay to quantify H1 complement in peripheral blood samples from healthy individuals and CML patients.

Main Results:

  • The MS-PRM assay demonstrated high reproducibility, sensitivity, and accuracy in quantifying H1 subtypes across different human cell lines.
  • Preliminary data indicated differences in the H1 complement between imatinib responders and non-responders in chronic myeloid leukemia (CML) patients.
  • Quantification values from the MS-PRM assay showed agreement with established methods like electrophoresis and Western blotting.

Conclusions:

  • The developed MS-PRM assay is a reliable tool for precise quantification of Histone H1 subtypes.
  • The observed differences in H1 complement in CML patients suggest that H1 subtypes may serve as predictive biomarkers for imatinib response.
  • Further research is warranted to explore the clinical utility of H1 complement composition for predicting therapeutic outcomes in CML.